



**Table S1. Primers used for qRT-PCR analysis.**

Gene	Forward	Reverse
PGC-1 $\alpha$	ATGAATGCAGCGGTCTTAGC	GGTCATCGTTTGTGGTCAGA
SOD2	CAGACCTGCCTTACGACTATGG	CTCGGTGGCGTTGAGATTGTT
Prx3	GGTTGCTCGTCATGCAAGTG	CCACAGTATGTCTGTCAAACAGG
Trx2	TGGGCTTCCCTCACCTCTAAG	CCTGGACGTAAAGGTCGTCA
GPx1	GTCTCTCTGAGGCACGATCCG	TTCCGCAGGAAGGTAACAGC
UCP2	CAGGTCACTGTGCCCTTACCAT	CACTACGTTCCAGGATCCCAAG
UCP4	GAATGCCTATCGCCGAGGA	AGTAGGAACTTGCTCGTCCGG
UCP5	TCCCAACTGCTCAGCGTG	GGTGCTTCTTGGTAATATCATAAACG
GAPDH	TGTGATGGGTGTGAACCACGAGAA	CATGAGCCCTTCCACAATGCCAAA




**Figure S1. The expressions of PGC-1 $\alpha$  are reduced in cortex and hippocampal CA3 areas of mice with chronic cerebral hypoperfusion.**

(A) Representative images of immunofluorescent staining for the PGC-1 $\alpha$  expressions in cortex and hippocampal CA3 areas of sham and BCAS groups. (B) Quantification of PGC-1 $\alpha$  expression. \* $p < 0.05$  as determined by t Mann-Whitney  $U$  test.  $n = 6$  in each group.




**Figure S2. *PGC-1α* does not alter anatomical structure and the numbers of neurons.**

(A) Representative images of H&E staining in cortex and hippocampal CA1 areas showed no abnormalities in WT, *PGC-1α<sup>fl/fl</sup>* or nPGC-1α groups. (B) Representative images of immunostaining for the NeuN-positive neurons in cortex and hippocampal CA1 areas. There were no obvious changes in neuron numbers among these 3 groups. n = 6 in each group.




**Figure S3. CBFs are down-regulated in 3 BCAS experimental groups in a similar manner.**

CBF was recorded at different time points, including before and at 2 h, 1 week, 2 weeks and 4 weeks after BCAS surgery. CBF significantly decreased in these 3 experimental groups relative to the sham group. The decreased trend was similar among these 3 experimental groups. \*\*\*p<0.001 as determined by two-way ANOVA. n = 6 in each group.



**Figure S4. PGC-1 $\alpha$  improves the executive function of mice with BCAS.**


(A) Trials to reach criteria at the acquisition and shift stages of ODRL test for the sham, WT+BCAS, *PGC-1 $\alpha$ <sup>fl/fl</sup>*+BCAS, and nPGC-1 $\alpha$ +BCAS mice. (B) Time to get reward at the acquisition and shift stages of ODRL test. \* $p < 0.05$ , \*\* $p < 0.01$  as determined by one-way ANOVA.  $n = 6$  in each group.



**Figure S5. The regulation of PGC-1 $\alpha$  expression alters the neurological outcomes in the BCAS mice model.**

(A) The typical swimming paths for the mice from Lentivirus-control, Lentivirus-control+BCAS, Lentivirus-PGC-1 $\alpha$  RNAi+BCAS, and Lentivirus-PGC-1 $\alpha$ +BCAS groups in the MWM during learning (top) and memory probe tests (bottom). (B) Escape latencies significantly increased in the Lentivirus-control+BCAS and Lentivirus-PGC-1 $\alpha$  RNAi+BCAS mice. \* $p < 0.05$  for the comparison between Lentivirus-PGC-1 $\alpha$  RNAi+BCAS and Lentivirus-


control+BCAS groups;  $##p<0.01$ ,  $###p<0.001$  for the comparison between Lentivirus-PGC-1 $\alpha$  RNAi+BCAS and Lentivirus-control groups;  $^{\Delta}p<0.05$  for the comparison between Lentivirus-PGC-1 $\alpha$ +BCAS and Lentivirus-PGC-1 $\alpha$  RNAi+BCAS groups, as determined by two-way ANOVA. (C) The comparisons of mean numbers of platform crossings among 4 groups during the probe test.  $*p<0.05$ ,  $**p<0.01$ ,  $***p<0.001$  as determined by one-way ANOVA. (D) The typical swimming paths for the mice from nPGC-1 $\alpha$ +BCAS, nPGC-1 $\alpha$ +BCAS+SR-18292, WT+BCAS, and WT+BCAS+SR-18292 groups in the MWM during learning (top) and memory probe tests (bottom). (E) Escape latencies significantly increased in the WT+BCAS+SR-18292 mice.  $*p<0.05$  for the comparison between nPGC-1 $\alpha$ +BCAS+SR-18292 and nPGC-1 $\alpha$ +BCAS groups;  $^{\#}p<0.05$ ,  $###p<0.001$  for the comparison between WT+BCAS+SR-18292 and nPGC-1 $\alpha$ +BCAS groups;  $^{\Delta}p<0.05$  for the comparison between WT+BCAS+SR-18292 and WT+BCAS groups, as determined by two-way ANOVA. (F) The comparison of mean numbers of platform crossings during the probe test.  $*p<0.05$ ,  $***p<0.001$  as determined by one-way ANOVA.  $n = 6$  in each group.



**Figure S6. PGC-1 $\alpha$  alters the gene expression profiles in hippocampus under basal conditions.**


(A) Cluster analysis for the differentially expressed mRNAs in hippocampus between PGC-1 $\alpha^{fl/fl}$  and nPGC-1 $\alpha$  groups were performed using microarray. One hundred up-regulated and 290 down-regulated genes were identified. (B) Go analysis showed the top 10 enriched molecular functions. (C) KEGG analysis showed the top 10 enriched pathways.  $n = 6$  in each group.

= 5 in each group.



**Figure S7. PGC-1 $\alpha$  reduces the activation of astrocytes.**

(A) Representative images of the GFAP-positive astrocytes in hippocampal CA1 areas in WT+BCAS, PGC-1 $\alpha^{fl/fl}$ +BCAS, nPGC-1 $\alpha$ +BCAS and sham mice. (B) The numbers of the GFAP-positive astrocytes. \* $p < 0.05$ , \*\* $p < 0.01$  as determined by one-way ANOVA.  $n = 6$  in each group.



**Figure S8. PGC-1 $\alpha$  attenuates the damage of white matter in BCAS mice.**

(A) Representative images of immunofluorescent staining for MBP in corpus callosum from the sham, WT+BCAS, PGC-1 $\alpha^{fl/fl}$ +BCAS, and nPGC-1 $\alpha$ +BCAS mice. (B) Representative images of immunofluorescent staining for MBP in caudoputamen.